Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.50 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6001031 | 1.00 | HTT (0.55) | HTTALDH1A1KMT2AMEN1EPHX1 | |
| SCHEMBL3532080 | 1.00 | HTT (0.55) | HTTALDH1A1KMT2AMEN1EPHX1 | |
| SCHEMBL24106055 | 0.95 | EPHX1 (0.51) | HTTALDH1A1KMT2AMEN1EPHX1 | |
| SCHEMBL1600934 | 0.89 | PDPK1 (0.59) | HTTALDH1A1SMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL2461645 | 0.89 | PDPK1 (0.59) | HTTALDH1A1SMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL598847 | 0.89 | PDPK1 (0.59) | HTTALDH1A1SMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL8613632 | 0.83 | HTT (0.56) | HTTALDH1A1KMT2AMEN1EPHX1 | |
| Pyridine SCHEMBL28149473 | 0.80 | PDPK1 (0.49) | HTTALDH1A1TSHR | |
| SCHEMBL2115700 | 0.80 | HTT (0.63) | HTTALDH1A1KMT2AMEN1EPHX1 | |
| SCHEMBL19120324 | 0.79 | ALDH1A1 (0.54) | HTTALDH1A1KMT2AMEN1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4332724-A | OXIDATION IN PRESENCE OF COBALT CATALYST | AMERICAN CYANAMID CO. (US) | 1982-06-01 | — | — | US | claimed |
| US-4254268-A | OXIDIZED BY POTASSIUM PERMANGANATE | AMERICAN CYANAMID COMPANY (US) | 1981-03-03 | — | — | US | claimed |
| EP-3151920-B1 | USE OF INHIBITOR OF APOPTOSIS PROTEIN (IAP) ANTAGONISTS IN HIV THERAPY | SANFORD BURNHAM MED RES INST (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250129099-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute | 2025-04-24 | — | — | US | disclosed |
| EP-4426707-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-09-11 | — | — | EP | disclosed |
| US-11912786-B2 | Inhibitor of apoptosis protein (IAP) antagonists | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230295181-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute | 2023-09-21 | — | — | US | disclosed |
| EP-3215510-B1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023081290-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-4143198-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-2925764-B1 | INHIBITOR OF APOPTOSIS PROTEIN (IAP) ANTAGONISTS | SANFORD BURNHAM MED RES INST (US) | 2023-03-01 | — | — | EP | disclosed |
| US-4091018-A | ANIMAL GROWTH PROMOTERS | AMERICAN CYANAMID COMPANY (US) | 1978-05-23 | — | — | US | disclosed |
| US-4089976-A | Synthesis of 1,2,3,4-tetrahydro-4-oxo-[or oxy-]-1-naphthylureas as novel growth-promoting compounds for animals | AMERICAN CYANAMID COMPANY (US) | 1978-05-16 | — | — | US | disclosed |
| US-4088786-A | Method for utilizing tetrahydro-4-imino-1-naphthylureas as growth promoting agents for animals | AMERICAN CYANAMID COMPANY (US) | 1978-05-09 | — | — | US | disclosed |
| US-4076952-A | ANIMAL GROWTH PROMOTERS | AMERICAN CYANAMID COMPANY (US) | 1978-02-28 | — | — | US | disclosed |
| US-4072711-A | ANIMAL GROWTH REGULATORS | AMERICAN CYANAMID COMPANY (US) | 1978-02-07 | — | — | US | disclosed |
| US-4051183-A | 1-BENZOYL-3-(1,2,3,4-TETRAHYDRO-4-OXO-1-NAPHTHYL)-UREA, A NOVEL AND USEFUL INTERMEDIATE FOR THE PREPARATION OF ANIMAL GROWTH PROMOTING AGENTS | AMERICAN CYANAMID COMPANY (US) | 1977-09-27 | — | — | US | disclosed |
| US-4049717-A | INTERMEDIATES FOR UREAS AND THIOUREAS | AMERICAN CYANAMID COMPANY (US) | 1977-09-20 | — | — | US | disclosed |
| US-4041070-A | ANIMAL GROWTH PROMOTERS, ENHANCING FEED EFFICIENCY | AMERICAN CYANAMID COMPANY (US) | 1977-08-09 | — | — | US | disclosed |
| US-3993677-A | ANIMAL GROWTH REGULATORS, HERBICIDES | AMERICAN CYANAMID COMPANY (US) | 1976-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129099-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | API5, XIAP, BIRC5 | HTT 3785/4885ALDH1A1 4338/4885KMT2A 3935/4885 |
| US-11912786-B2 | Inhibitor of apoptosis protein (IAP) antagonists | API5, XIAP, BIRC5 | HTT 2134/4885ALDH1A1 4556/4885KMT2A 4599/4885 |
| US-20230295181-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | API5, XIAP, BIRC5 | HTT 3785/4885ALDH1A1 4338/4885KMT2A 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.